Home » Topics » BioWorld Science

BioWorld Science
RSS

New AXL/c-Met inhibitors disclosed by Shanghai Institute of Materia Medica

Dec. 16, 2019

Decoding EGFR's skin toxicity

Dec. 16, 2019

Beijing Innocare Pharmaceutical Technology discovers IDO-1 inhibitors

Dec. 16, 2019

Shanghai Zhimeng Biopharma describes potassium channel activators

Dec. 16, 2019

Unexpected Ibrance MOA

Dec. 16, 2019

GDF1 unveiled as a therapeutic target for treating AML

Dec. 16, 2019

Blood-brain barrier disruption could be Alzheimer's target

Dec. 16, 2019

Cirmtuzumab plus paclitaxel safe and well-tolerated in phase I study in breast cancer

Dec. 16, 2019

ARX-788 well-tolerated in phase I study in Chinese patients with metastatic HER2+ breast cancer

Dec. 16, 2019

Results reported from ongoing phase I study of FT-4202

Dec. 16, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...
CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research
BioWorld Science
Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...